FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person FITZPATRICK LINDA A	2. Issuer Name and Ticker or Trading Symbol SUTRO BIOPHARMA, INC. [STRO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) C/O SUTRO BIOPHARMA, INC AVENUE, SUITE 150	3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021						X Officer (give title below) Other (specify below) Chief People & Comm. Officer			
(Street) SOUTH SAN FRANCISCO, CA	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	h/Day/Year) Execution Date, if Code any (Month/Day/Year) (Instr. 8)		tion	4. Securi (A) or D (Instr. 3, Amount	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
Common Stock	01/19/2021		М		1,652	А	\$ 4.36	15,616	D	
Common Stock								10,383	Ι	Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or	indirectly.	
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

-	(e.g., puts, cans, warrants, options, convertible securities)														
1. Title of Derivative	2. Conversion	 Transaction Date 	3A. Deemed Execution Date, if	4. Transact							8. Price of Derivative	9. Number of Derivative	10. Ownership	11. Nature of Indirect	
Security	or Exercise	(Month/Day/Year)	anv	Code			(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial	
	Price of	(· · · · · · · · · · · · · · · · · · ·	(Month/Day/Year)	(Instr. 8					(Instr. 3 and 4)				Derivative		
` '	Derivative				Acquired						· /	Owned	Security:	(Instr. 4)	
	Security					(A) or							Following	Direct (D)	· · · ·
	-				Disposed							Reported	or Indirect		
					of (D)							Transaction(s)	(I)		
					(Instr. 3, 4,							(Instr. 4)	(Instr. 4)		
				and 5)											
											Amount				
								D (т ·		or				
									Expiration	Title	Number				
								Exercisable	Date		of				
				Code	V	(A)	(D)				Shares				
Stock															
										Commen					
Option	\$ 4.36	01/19/2021		Μ			1,652	<u>(2)</u>	02/08/2021	Common	1,652	\$ 0	0	D	
(right to							, -			Stock	, -				
buy)															

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
FITZPATRICK LINDA A C/O SUTRO BIOPHARMA, INC. 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO, CA 94080			Chief People & Comm. Officer					

Signatures

/s/ Edward C. Albini as attorney-in-fact for Linda Fitzpatrick	01/20/2021
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997.
- (2) The option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.